A committee of the European Medicines Agency has recommended approving Uplizna (inebilizumab-cdon) for adults with neuromyelitis optica spectrum disorder (NMOSD) who test positive for aquaporin-4 water channel autoantibodies (AQP4-IgG). This recommendation from the Committee for Medicinal Products for Human Use, known as CHMP, will now be reviewed by…
AQP4 autoantibodies
Recent Posts
- Advocates join forces to create, celebrate World NMOSD Awareness Day
- With a compromised immune system, constant infections are my nemesis
- Approved NMOSD therapies better than rituximab at preventing relapses
- Embracing an opportunity for advocacy on Rare Disease Day
- Cognitive issues affect nearly 1 in 3 with NMOSD, study finds